Audit: QRS - Erythritol for Health & Longevity

Audit conducted on 09/09/2026 04:16 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	83
Failed	0
N/A	10
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	All protocol values (10–30 g daily, after meals, two to three servings), time-to-effect values, gate items, tier items, biomarker rows and cadence trace to ER lines 319–323, 345–355, 398, 430–446.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	“Association with…” retained for liver fat, cancer mortality and cognitive decline; “possible blunting of antiplatelet medication” retained; marker_7_target keeps “No established target for this purpose”.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Contraindication severities and the 12-month post-event window are carried across unchanged; no interaction is upgraded or downgraded.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Stop items come only from the ER “Populations who should avoid erythritol” list; caution items only from the ER interaction bullets; no modifying-factor content is repurposed.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No PMIDs, NCT identifiers, author names or commercial brands appear anywhere in the QRS.
1.6	The QRS does not introduce new attributions.	🟢	No funder, research group or expert attribution is carried into the sheet.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Measured, two-sided register of the ER is preserved, including its British spellings (“ischaemic”, “diarrhoea”).
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Ranges and thresholds are given without alarm; benefits and risks are presented in parallel tiers.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	No prescriptive verbs directed at a patient; the protocol cells describe the approaches the ER documents.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	Cadence and monitoring content is stated descriptively (“Baseline panel before habitual use begins; repeated after 8 to 12 weeks…”).
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	No “recommended”, “advised” or “should” constructions in the QRS body.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronouns anywhere in the document.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Technical terms that remain (eGFR, ApoB, hs-CRP, myocardial infarction) are ER-verbatim biomarker or decision-gate terms; the At-A-Glance line is fully plain-language.
2.8	Information is presented in a concise and very compact manner	🟢	Benefits and risks are reduced to ER headings only; gate items are label-plus-parenthetical; no mechanistic prose.
2.9	It DOES NOT address the reader directly	🟢	Confirmed; the sheet speaks about the intervention, not to a reader.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Optimal functional ranges (fasting insulin 2–5 µIU/mL, ApoB under 80 mg/dL) rather than conventional lab flags signal the proactive audience.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Dose splitting, post-meal timing and a seven-marker baseline panel presume a willing, effortful audience.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	Platelet reactivity testing and quantitative functional ranges are beyond general-population framing.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	The unresolved cardiovascular signal is stated in At-A-Glance and tiered in Risks rather than dismissed or amplified.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	“Anti-aging” does not occur; the title uses “Health & Longevity”.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢	Gate, tier and monitoring content uses formal terminology; the plain wording in At-A-Glance is required by item 7.4 and is ER-Conclusion-derived.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All fixed strings match the template byte-for-byte (lines 440, 477, 519, 539, 551, 572, 591, 595–597, 688).
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	Every template span is present; marker_#_* is correctly expanded to marker_1–7 and qualitative_item_# to qualitative_item_1–5.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	A full diff against the template shows differences only inside variable spans, the title, and the metadata block.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No source ER section feeding the QRS is empty.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	action_1/2/3 labels reproduce the ER bold labels “Conventional food-substitution approach”, “Best time of day”, “Half-life and dose splitting” verbatim; gate items reproduce the ER interaction bold labels verbatim.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Time-to-effect labels are lifted from the ER’s own wording at line 398; biomarker names match the ER table exactly.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	No emoji in the QRS; the ER’s ⚠️ Conflicted markers are correctly dropped.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Every section is at its condensed floor: tier lines are ER headings only, gate items are label-plus-parenthetical with all trailing rationale stripped, and monitoring rows carry no Context/Notes column.

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Lines 2–14, immediately after the doctype and before the template comment on line 16.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening “—” at line 3, closing “—” at line 13; the descriptive text on line 2 precedes the opening delimiter.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Enclosed in an HTML comment; none of its values are echoed by a visible element other than the template-mandated date and model in the subline.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration: "00:02" is quoted, and it contains a colon; all other values are bare and trimmed.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	Line 4: er_filename: erythritol_2026-0909-0009_Opus_ER.md, matching the ER frontmatter filename.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	Line 5: qrs_prompt_version: 26.7.02, matching the QRS.md version badge.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	Line 6: qrs_creation_date: 2026-0909-0404, correct format.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	Line 7: qrs_creator_ai_nickname: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	“Opus” is a single word with no version or qualifier.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	Line 8: qrs_creator_ai_fullname: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” is nickname plus version with no qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	Line 9 matches the actual file name erythritol_2026-0909-0009_Opus_QRS.html.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Re-verified across all nine keys including git_user and git_issue; no stray whitespace or unnecessary quoting.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	Line 22: “Erythritol for Health & Longevity - Quick Reference Sheet”, matching ER canonical_topic with the ampersand encoded.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	Line 417: “Erythritol for Health & Longevity”.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	Line 421: “09/09/2026”, the correct rendering of 2026-0909-0404.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Line 425: “Opus 5”, matching the frontmatter value.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	The header carries only the title and the template subline; the ER’s “Also known as” line is not reproduced.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Line 433 condenses ER lines 468–470: what it is, the three supported benefits, and the unresolved cardiovascular question.
7.2	[at_a_glance] is no longer than 60 words	🟢	Exactly 60 words by word count.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Each of the six assertions maps to a distinct clause in the ER Conclusion (lines 468 and 470).
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	No acronyms; “blood sugar”, “sugar alcohols”, “mouth bacteria”, “tooth-eroding acid”, “heart attacks and strokes” are all lay terms.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No trial name, year or sample size appears.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No hazard ratios, confidence intervals or effect sizes appear.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All five items come from the “Populations who should avoid erythritol” list at ER lines 319–323.
8.2	[stop_items] represent the Contraindications from the ER	🟢	All five ER avoid-populations are represented, none added.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Lines 542–546 are five discrete <li> elements inside the span.
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Trailing rationale is stripped throughout: “as an absolute contraindication”, “where the thrombotic signal is least acceptable and alternatives exist”, “since renal clearance is the only elimination route”, “in whom polyols are a recognised symptom trigger”.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	“at any dose”, “within 12 months”, “below 30 mL/min/1.73 m²”, “(factor V Leiden, antiphospholipid syndrome)” and “diarrhoea-predominant subtype” are all retained.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation inside parentheses in this section.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The ER names five such populations, and the section is correctly populated rather than left empty.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All nine items come from the ER interaction bullets at lines 299–315.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	All nine ER interaction bullets are present; none overlaps the five contraindication entries.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Lines 554–562 are nine discrete <li> elements.
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Each item is reduced to the ER bold label; the Caution/Monitor grading and all mechanistic and mitigation prose are stripped.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Every ER example-drug list is carried through intact, including the antiplatelet, anticoagulant, laxative, antacid, polyol, GLP-1 and supplement lists.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation inside parentheses in this section.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The ER names nine interactions, and the section is correctly populated.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	All three cells derive from the ER Therapeutic Protocol bullets at lines 345, 353 and 355.
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Dose (10–30 g daily), timing (after meals) and dose splitting (two to three servings) are the three decision-relevant levers; the remaining ER bullets are approach descriptions or modifier discussion.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies more than three actionable aspects, so no set is unused.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	All nine action variables carry ER-derived content; no placeholder remains.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Glycemic sparing (immediate), dental benefits (12–36 months) and gut-hormone/gastric-emptying effects (within an hour) are the three aspects the ER states at line 398.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Glycemic sparing maps to a High-tier benefit; dental and gut-hormone effects are both Medium-tier and follow the ER’s own within-tier order.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies exactly three time-to-effect aspects, so no set is unused.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	All nine time variables carry ER-derived content drawn from ER line 398.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER provides time-to-effect information, so the section is correctly retained.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	All eight entries are the ER’s own benefit sub-headings from lines 153–201.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans are present and populated at lines 521–532.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Only the ER headings survive; all Magnitude figures, funding notes and mechanistic prose are dropped.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses remain in any benefits entry.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four ER benefit tiers contain items, so no span needs hiding.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	All nine entries are the ER’s own risk sub-headings from lines 225–279.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans are present and populated at lines 574–585.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Hazard ratios, confidence intervals, cohort descriptions and patent-interest notes are all stripped; only the headings remain.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses remain in any risks entry.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four ER risk tiers contain items, so no span needs hiding.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	Rows and cadence derive from the ER Monitoring Protocol & Defining Success section, lines 426–438.
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All seven ER table rows are present: fasting glucose, HbA1c, fasting insulin, ApoB, hs-CRP, eGFR and platelet reactivity, with targets and rationales matching the ER verbatim.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Line 682 reproduces the ER cadence from lines 426 and 428: baseline, 8–12 weeks, then every 6–12 months, or within 4 weeks of a relevant change.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	All five entries come from the ER “Qualitative markers worth tracking alongside the labs” list at lines 442–446.
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All five ER qualitative markers are present and none is added.

Issues 09/09/2026 04:16

Pass rate 100.00%. No issues found.

Issues 09/09/2026 04:06

1. 1.1 / 1.3 / 7.3 — At-a-glance overstates absorption: [at_a_glance] at line 433 says erythritol is “absorbed whole”, which strengthens the ER Conclusion’s “absorbed almost completely” (ER line 468) and contradicts the ER’s “About 90% is absorbed passively in the small intestine” with a “small unabsorbed remainder” reaching the colon (ER line 131) — the very fraction behind the QRS’s own High risk item “Dose-dependent gastrointestinal symptoms”.

Fixes 09/09/2026 04:06

1. 1.1 / 1.3 / 7.3 — At-a-glance absorption wording: Changed [at_a_glance] at line 433 from “absorbed whole” to “absorbed almost completely”, matching the ER Conclusion verbatim and restoring consistency with the ER’s ~90% absorption figure. The section remains within the 60-word limit.